S

Shanghai MicroPort MedBot Group Co Ltd
HKEX:2252

Watchlist Manager
Shanghai MicroPort MedBot Group Co Ltd
HKEX:2252
Watchlist
Price: 8.17 HKD -10.71% Market Closed
Market Cap: 7.9B HKD
Have any thoughts about
Shanghai MicroPort MedBot Group Co Ltd?
Write Note

Shanghai MicroPort MedBot Group Co Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shanghai MicroPort MedBot Group Co Ltd
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
S
Shanghai MicroPort MedBot Group Co Ltd
HKEX:2252
Cost of Revenue
-ÂĄ89.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Cost of Revenue
-ÂĄ486.1m
CAGR 3-Years
-51%
CAGR 5-Years
-45%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Cost of Revenue
-ÂĄ3.7B
CAGR 3-Years
1%
CAGR 5-Years
-6%
CAGR 10-Years
-14%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Cost of Revenue
-ÂĄ12.8B
CAGR 3-Years
-15%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
J
Jafron Biomedical Co Ltd
SZSE:300529
Cost of Revenue
-ÂĄ518.3m
CAGR 3-Years
-12%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Cost of Revenue
-ÂĄ5.9B
CAGR 3-Years
-26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shanghai MicroPort MedBot Group Co Ltd
Glance View

Market Cap
7.8B HKD
Industry
Health Care

Shanghai MicroPort MedBot (Group) Co., Ltd. operates as a surgical robot company dedicated to designing, developing and commercializing surgical robots to assist surgeons in performing complex surgical procedures. The company is headquartered in Shanghai, Shanghai and currently employs 756 full-time employees. The company went IPO on 2021-11-02. The firm's main business is the design, development and commercialization of innovative surgical robots. The firm's products include Toumai Laparoscopic Surgical Robot, DFVision 3D Electronic Laparoscope and Honghu Orthopedic Surgical Robot. The firm's surgical robots are used in multiple minimally invasive surgery fields, including endoscopic surgery, orthopedic surgery, pan-vascular surgery, natural cavity surgery and percutaneous puncture surgery. In addition, the Company also provides education and training services for its surgical robot MedBot.

Intrinsic Value
4.69 HKD
Overvaluation 43%
Intrinsic Value
Price
S

See Also

What is Shanghai MicroPort MedBot Group Co Ltd's Cost of Revenue?
Cost of Revenue
-89.9m CNY

Based on the financial report for Dec 31, 2023, Shanghai MicroPort MedBot Group Co Ltd's Cost of Revenue amounts to -89.9m CNY.

What is Shanghai MicroPort MedBot Group Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
-498%

Over the last year, the Cost of Revenue growth was -498%.

Back to Top